Prostamax is a synthetic Khavinson peptide bioregulator marketed for prostate and urogenital support, with the community primarily using it to bolster prostate health. Users typically dose 1 mg per day, with reported ranges from 500 µg to 5 mg and most taking it daily, while a clinician protocol cites a 20 mg subcutaneous daily regimen. The key limitation is that there is no FDA‑approved indication, so all human use is off‑label or compounded, and injection‑site reactions have not emerged as a consistent theme in reports.
Data last updated
Measured on 4 of 6 axes
Evidence shape
The evidence for Prostamax is animal-only, with no human published studies. There is one mapped indication, which is supported by preclinical or mechanistic research in animals. No completed trials have been conducted, indicating a lack of clinical evidence to support its use.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How Prostamax is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
In clinician practice, Prostamax is typically given as a 20 mg subcutaneous injection; no specific frequency or cycling protocol is documented.
Most community users administer about 1 mg of Prostamax subcutaneously once daily (dose range 0.5–5 mg); a smaller subset takes 5 mg twice daily, and several respondents did not state a specific schedule.